Showing results 61 to 80 of 338
  Utilisation du propeptide N-terminal du procollagène de type 1 (P1NP) comme marqueur de formation osseuse chez le patient insuffisant rénal : différence entre le dosage total et le dosage « intact ».DELANAYE, Pierre  ; CARLISI, Ignazia ; ROUSSELLE, Olivier et alPoster (2012) Detailed reference viewed: 15 (3 ULg)Detection of decreased glomerular filtration rate in intensive care units: interest of cystatin CDELANAYE, Pierre ; CAVALIER, Etienne ; et alPoster (2012) Detailed reference viewed: 15 (7 ULg)Compliance of the hemodialysis patient to the native vitamin D therapyDELANAYE, Pierre ; DUBOIS, Bernard ; KRZESINSKI, Jean-Marie et alPoster (2012) Detailed reference viewed: 23 (2 ULg)Adhésion thérapeutique du patient hémodialyséDELANAYE, Pierre ; CAVALIER, Etienne ; DUBOIS, Bernard et alPoster (2012) Detailed reference viewed: 14 (2 ULg) L'estimation du débit de filtration glomérulaire en 2012: quelle valeur ajoutée pour la nouvelle équation CKD-EPIDELANAYE, Pierre ; ; et alin Néphrologie & Thérapeutique (2012), 8 Mesurer ou estimer le debit de filtration glomerulaire (DFG) reste l’un des meilleurs moyens d’apprehender la fonction glomerulaire du rein. En 2009, l’equation Chronic Kidney Disease Epidemiology (CKD ... [more ▼] Mesurer ou estimer le debit de filtration glomerulaire (DFG) reste l’un des meilleurs moyens d’apprehender la fonction glomerulaire du rein. En 2009, l’equation Chronic Kidney Disease Epidemiology (CKD-EPI) a ete proposee en lieu et place de l’equation Modification of Diet in Renal Disease (MDRD) pour estimer le DFG. Cette nouvelle equation fait partie desormais des toutes dernieres recommandations de la Haute Autorite de sante (HAS). Par rapport a MDRD, la formule CKD-EPI est sensee moins sous-estimer le DFG mesure, principalement dans les valeurs les plus hautes de DFG. Dans cette revue critique de la litterature, nous presenterons et discuterons les performances de cette nouvelle equation. Sur base des articles publies entre 2009 et 2012, nous en soulignerons les avantages, notamment en terme d’estimation de la prevalence de la maladie renale chronique (MRC), mais aussi les faiblesses, principalement dans certaines populations specifiques. En effet, toutes ces equations reposant sur la mesure de la creatinine serique restent des estimations et le nephrologue doit donc garder son sens critique dans l’interpretation de ces resultats. [less ▲] Detailed reference viewed: 19 (0 ULg)Vigilance et dialogue entre biologiste et clinicien s'imposent au quotidien. Cas vécus au laboratoire.CAVALIER, Etienne in Journal de Biologie Médicale (2012), 1(2), 104-6 Detailed reference viewed: 9 (0 ULg)Interpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: importance of the reference (normal) valuesCAVALIER, Etienne ; DELANAYE, Pierre ; VRANKEN, Laura et alin Nephrology Dialysis Transplantation (2012), 27 Background. The recommended target range for serum parathyroid hormone (PTH) in dialysis patients has changed from 150 to 300 pg/mL in the KDOQI guidelines to two to nine times the upper normal limit in ... [more ▼] Background. The recommended target range for serum parathyroid hormone (PTH) in dialysis patients has changed from 150 to 300 pg/mL in the KDOQI guidelines to two to nine times the upper normal limit in the KDIGO ones. Although inclusion/exclusion criteria for the reference population are highly important, they are usually not mentioned in the commercial kits. In this study, we used the same reference population of vitamin D-replete normal subjects to establish reference values for 10 commercial PTH kits. We evaluated whether this may improve the classification of dialysis patients according to the KDIGO compared to the use of reference values proposed by the manufacturers. Methods. We measured serum PTH with 10 different kits in 149 haemodialysis patients, and 240 25-OH-vitamin D-replete (>75 nmol/L) individuals with an estimated glomerular filtration rate >60 mL/min/1.73 m2. Results. For the 10 kits, our upper normal limit was lower than those of the manufacturers. The difference was, however, variable from one kit to another. The two kits that yielded the lowest and the highest absolute concentrations classified differently 84/149 patients (56.4%) according to the KDOQI and 53/149 (36.2%) according to the KDIGO using the manufacturers’ normal value.Using our normal values significantly decreased the discrepancies with 24/149 patients (16.1%) being still classified differently. Taking the measurement uncertainty into consideration, 8% of the patients only remained differently classified by these two kits. Conclusions. Using the same vitamin-D-replete population to establish the reference range for 10 commercial PTH kits significantly improved the classification of haemodialysis patients according to the KDIGO target range. [less ▲] Detailed reference viewed: 48 (5 ULg) Good interpretation of a biological result: generality and specificity to NephrologyCAVALIER, Etienne in DELANAYE, Pierre (Ed.) Clinical Chemistry and Nephrology: the essential link (2012) Detailed reference viewed: 8 (1 ULg)Vascular calcifications in chronic kidney disease: can the Biologist be of some help?; ; et al in DELANAYE, Pierre (Ed.) Clinical Chemistry and Nephrology: the essential link (2012) Detailed reference viewed: 14 (2 ULg)Analytical evaluation of the new Abbott Architect 25-OH vitamin D assayCAVALIER, Etienne ; CARLISI, Ignazia ; BEKAERT, Anne-Catherine et alin Clinical Biochemistry (2012), 45 Objectives: Validation of the Architect 25-OH vitamin D assay. Design and methods: Determination of repeatability, reproducibility, accuracy profile and 25(OH)-vitamin D2 recovery on native samples ... [more ▼] Objectives: Validation of the Architect 25-OH vitamin D assay. Design and methods: Determination of repeatability, reproducibility, accuracy profile and 25(OH)-vitamin D2 recovery on native samples. Comparison with DiaSorin Liaison and RIA. Results and conclusion: Coefficients of variation: b6% (13.6 ng/mL) and 2.2% (78.1 ng/mL). Functional sensitivity: 5 ng/mL. Accuracy profile shows that the method is validated between 13.6 and 78.1 ng/mL. Recovery of 25(OH)D2: 75,8%( 95% CI: 61.9–89.7%). Good correlation with DiaSorin RIA and Liaison b50 ng/mL; above this threshold a systematic positive bias was observed. [less ▲] Detailed reference viewed: 42 (1 ULg)Séminaire de Chimie médicale - Les ImmunoassaysCAVALIER, Etienne Learning material (2011) Detailed reference viewed: 13 (0 ULg)Vitamin D measurement: Laboratory issuesCAVALIER, Etienne Conference (2011, December 02) Detailed reference viewed: 18 (4 ULg)Vitamine D et maladies infectieusesCAVALIER, Etienne ; MOUTSCHEN, Michel ; Brunel, Elodie Conference (2011, November 24) Detailed reference viewed: 34 (6 ULg)Recommendations on Vitamin D testing and analytical validation of the Architect 25 OH Vitamin D assayCAVALIER, Etienne Conference (2011, November 17) Detailed reference viewed: 13 (1 ULg)Vitamin D, 1-84 PTH and KDIGO GuidelinesCAVALIER, Etienne Conference (2011, November 16) Detailed reference viewed: 19 (0 ULg) Vitamin D, cardiovascular disease and mortality; ; et al in Clinical Endocrinology (2011), 75(5), 575-84 A poor vitamin D status, i.e. low serum levels of 25-hydroxyvitamin D (25[OH]D), is common in the general population. This finding is of concern not only because of the classic vitamin D effects on ... [more ▼] A poor vitamin D status, i.e. low serum levels of 25-hydroxyvitamin D (25[OH]D), is common in the general population. This finding is of concern not only because of the classic vitamin D effects on musculoskeletal outcomes, but also because expression of the vitamin D receptor (VDR) and vitamin D metabolizing enzymes in the heart and blood vessels suggests a role of vitamin D in the cardiovascular system. VDR-knockout mice suffer from cardiovascular disease (CVD) and various experimental studies suggest cardiovascular-protection by vitamin D, including anti-atherosclerotic, anti-inflammatory and direct cardio-protective actions, beneficial effects on classic cardiovascular risk factors as well as suppression of parathyroid hormone (PTH) levels. In epidemiological studies, low levels of 25(OH)D are associated with increased risk of CVD and mortality. Data from randomized controlled trials (RCTs) are sparse and have partially, but not consistently, shown some beneficial effects of vitamin D supplementation on cardiovascular risk factors (e.g. arterial hypertension). We have insufficient data on vitamin D effects on cardiovascular events, but meta-analyses of RCTs indicate that vitamin D may modestly reduce all-cause mortality. Despite accumulating data suggesting that a sufficient vitamin D status may protect against CVD, we still must wait for results of large-scale RCTs before raising general recommendations for vitamin D in the prevention and treatment of CVD. In current clinical practice the overall risks and costs of vitamin D supplementation should be weighed against the potential adverse consequences of untreated vitamin D deficiency [less ▲] Detailed reference viewed: 24 (1 ULg)Comparison between the new AccuChek Inform II glucose meter and the Rapidlab 865 blood gas analyzer: implications for use of the Inform II in tight glycemic controlDE BACKER, Benjamin ; ; HALENG, Jeanine et alPoster (2011, October 15) Detailed reference viewed: 21 (4 ULg)Les biomarqueurs de la lésion rénale: limites actuelles et perspectivesCAVALIER, Etienne Conference (2011, October 03) Detailed reference viewed: 4 (2 ULg)New insights on the stability of the (1-84) PTH as determined with an automated 3rd generation PTH assayCAVALIER, Etienne ; CARLISI, Ignazia ; BEKAERT, Anne-Catherine et alin Clinical Chemistry (2011, October), 57(S10), 190 Detailed reference viewed: 8 (0 ULg)Analytical validation of Accu-check Inform II meters and strips before their use in the wards: pratical experience of the CHU de LiègeCAVALIER, Etienne ; PONCIN, Joseph ; MUSSO, Giuseppe et alin Clinical Chemistry (2011, October), 27(S10), 143 Detailed reference viewed: 30 (11 ULg) |
||
